MedTrace Logo

Neurocognition and Work Productivity in Major Depressive Disorder (MDD)

NCT01468610 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2015-04-10

No results posted yet for this study

Summary

This study will investigate the relationships between subjective cognitive complaints, neurocognitive deficits, and work productivity in participants with Major Depressive Disorder (MDD), before and after 8 weeks of treatment with an antidepressant medication. Our hypothesis is that, in working participants with MDD of at least moderate severity, neurocognitive deficits will predict poorer work functioning and productivity.

Conditions

Interventions

DRUG

desvenlafaxine

50-100 mg daily for 8 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Raymond W Lam, MD, FRCPC · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-09-30
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468610 on ClinicalTrials.gov